文献速递口腔修复与种植口腔颌面外科

新型双相磷酸钙用于上颌窦底提升的微CT与组织形态学评估

Evaluation of a new biphasic calcium phosphate for maxillary sinus floor elevation: Micro-CT and histomorphometrical analyses.
PubMed 文献 · Clin Oral Implants Res · 2018-04-11

本研究纳入20例上颌窦底提升患者,分别使用BCP60/40或BCP20/80,术后6.5个月取活检行微CT和组织形态学分析。结果显示BCP20/80组在最近颅侧骨量和类骨质体积分别高9.7%和0.8%,而移植物体积、破骨细胞数和血管数两组相似,提示BCP20/80短期成骨潜力更优。

要点

  • BCP20/80在最近颅侧骨量比BCP60/40高9.7%,类骨质体积高0.8%。
  • 两组移植物体积、破骨细胞数和血管数相似。
  • BCP20/80可能因更快的骨改建速率或更早的骨形成而短期成骨更优。

核心结论

  • BCP20/80在MSFE患者中比BCP60/40表现出更强的成骨潜力,可能与更快的骨改建速率或更早的骨形成有关。

研究设计与样本

  • 研究纳入20例接受上颌窦底提升的患者,BCP60/40组10例,BCP20/80组10例,术后6.5个月(26周)取活检行微CT和组织形态学分析。

主要发现

  • BCP20/80组活检最近颅侧骨量比BCP60/40组高9.7%,类骨质体积高0.8%。
  • 两组移植物体积、破骨细胞数和血管数相似。

关键数值与推荐

  • 骨量和类骨质体积差异分别为9.7%和0.8%,对象为活检最近颅侧区域。

临床怎么用

  • BCP20/80可作为上颌窦底提升植骨材料的短期优选,但长期效果需进一步观察。

局限性

  • 样本量较小(每组10例),随访仅6.5个月,不能排除BCP60/40长期赶超的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Synthetic biphasic calcium phosphate (BCP) with a hydroxyapatite/ß-tricalcium phosphate (HA/ß-TCP) ratio of 60/40 (BCP60/40) is successfully used as alternative for autologous bone in patients undergoing maxillary sinus floor elevation (MSFE) for dental implant placement. A high percentage of HA in BCP60/40 may hamper efficient scaffold remodeling. Osteogenesis and neovascularization are pivotal in effective bone regeneration. We aimed to investigate whether differences exist in osteogenic and/or vasculogenic potential of BCP60/40 and BCP20/80 in patients undergoing MSFE. MATERIALS AND METHODS: Twenty patients undergoing MSFE were treated with BCP60/40 (n = 10) or BCP20/80 (n = 10). Bone and graft volumes were determined by micro-computed tomography and histomorphometrical analysis of biopsies of the augmented region. Osteoid volumes, number of osteoclasts, and blood vessels were determined by histomorphometrical analysis. The biopsies were taken 6.5 months (26 weeks) postoperatively prior to dental implant placement. RESULTS: Bone and osteoid volumes were 9.7% and 0.8% higher at the most cranial side of the BCP20/80 biopsies compared to the BCP60/40 biopsies. Graft volumes, number of osteoclasts, and blood vessels were similar in both groups. CONCLUSIONS: BCP20/80 showed enhanced osteogenic potential in patients undergoing MSFE compared to BCP60/40, due to either a faster bone remodeling rate or an earlier start of bone formation in BCP20/80-treated patients, suggesting that a higher TCP content positively contributes to the bone remodeling rate. Therefore, BCP20/80 might perform better, at least in the short term, as a scaffold for bone augmentation in the MSFE model than BCP60/40 as more bone is formed, and more osteoid is deposited at the cranial side in BCP20/80-treated patients compared to BCP60/40-treated patients. However, catch-up of BCP60/40 in the long term cannot be ruled out.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Helder MN, van Esterik FAS, Kwehandjaja MD, et al. Evaluation of a new biphasic calcium phosphate for maxillary sinus floor elevation: Micro-CT and histomorphometrical analyses. Clin Oral Implants Res. 2018. PMID: 29638012. doi:10.1111/clr.13146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。